Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 5 of 6

Economic information and modeling report

47 evidence topics · 22 sources

Modeling overview

Summary: ICER assessment, other published economic evaluations, and commercial forecasts

The Institute for Clinical and Economic Review (ICER) assessed baxdrostat and lorundrostat for hypertension in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and ICER's meeting slides state that the final report would be published “on or around November 30, 2026”. ICER rated the evidence for lorundrostat or baxdrostat compared with spironolactone, eplerenone, or amiloride as “Promising but Inconclusive” in participants with resistant hypertension or intolerance of a third first-line drug (Populations 1 and 2), as “comparable or inferior” to amlodipine in participants not yet treated with a third drug (Population 3), and as insufficient to distinguish lorundrostat from baxdrostat. ICER's lifetime model used the 50 mg once-daily dose of lorundrostat and a placeholder price equal to the baxdrostat wholesale acquisition cost ($10,950 per year). At that price, lorundrostat cost $1,419,000 per QALY gained compared with spironolactone and $1,492,000 compared with amiloride, and was “More costly, less effective” than eplerenone, which ICER attributed to a 10% first-cycle discontinuation probability for lorundrostat against 7.7% for eplerenone. Lorundrostat was cost-effective in 0.0% of probabilistic simulations at $150,000 per evLY gained, and the health-benefit price benchmark for lorundrostat was $760 to $1,600 per year (85.7% to 93.0% below the placeholder price), against $1,400 to $2,500 per year for baxdrostat. Mineralys commented that the model “does not fully capture the clinical and economic benefits of ASIs”, that first-cycle discontinuation of lorundrostat (10%) was based on Launch-HTN and that of eplerenone and amiloride (7.7%) on a study of Swedish patients receiving calcium channel blockers, and that models should incorporate dynamic pricing; a commenting coalition, No Patient Left Behind, estimated a societal value-based price of $18,767 to $26,913 per year. A 2026 review states that cost-effectiveness evidence for aldosterone synthase inhibitors is still needed. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified; a 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, 12 of 14 cost-utility analyses evaluating renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective), $12,900 per QALY for ultrasound renal denervation, $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY for team-based care with non-physician titration, and cost savings of $10,162 per person for pharmacist prescribing. No sales forecast from Mineralys was identified; GlobalData forecast lorundrostat sales of $601 million in 2030, and Visible Alpha consensus projected risk-adjusted sales of $122 million in 2027 and $365 million in 2028, with analysts expecting annual revenue of $1.1 billion by 2030.

ICER cost-effectiveness model: structure, perspective, and populations

“We developed a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models” (opens the source at this quote in a new tab)

“Costs and outcomes were discounted at 3% per year. Model cycle length was three months. The analysis was conducted from a US health care sector perspective over a lifetime time horizon.” (opens the source at this quote in a new tab)

“Populations 1 and 2 were therefore reduced to a single modeled population. Population 3 was not modeled as the comparative effectiveness review rated baxdrostat and lorundrostat as “comparable or inferior” to amlodipine and, consistent with the Model Analysis Plan, cost-effectiveness in this population was to be evaluated only if the aldosterone synthase inhibitors were superior to amlodipine.” (opens the source at this quote in a new tab)

“As shown in Figure 4.1, the model included seven primary health states: 1) hypertension alone, 2) stroke, 3) myocardial infarction (MI), 4) other symptomatic coronary heart disease (CHD), 5) heart failure (HF), 6) end-stage kidney disease (ESKD), and 7) death.” (opens the source at this quote in a new tab)

“Baseline characteristics were informed by the Bax24, BaxHTN, and Launch-HTN clinical trials” (opens the source at this quote in a new tab)

“For each intervention we modeled the dose most likely to be used in clinical practice, namely the 50 mg dose for lorundrostat and the 2 mg dose for baxdrostat, both administered as once daily tablets.” (opens the source at this quote in a new tab)

ICER cost-effectiveness model: treatment effect inputs

ParameterQuoted input
SBP reduction for lorundrostat vs. placebo (mm Hg)“9.0, (95% CrI: 1.7, 16.4)”
SBP reduction for baxdrostat vs. placebo (mm Hg)“11.0 (95% CrI: 7.3, 14.6)”
SBP reduction for spironolactone vs. placebo (mm Hg)“10.1 (95% CrI: 6.7, 13.1)”
SBP reduction for eplerenone vs. placebo (mm Hg)“8.8 (95% CrI: 2.3, 15.5)”
SBP reduction for amiloride vs. placebo (mm Hg)“6.6 (95% CrI: 1.4, 11.6)”
Hazard ratio for stroke, per 5 mm Hg SBP reduction“0.87 (95% CI: 0.84, 0.91)”
Hazard ratio for ischemic heart disease, per 5 mm Hg SBP reduction“0.92 (95% CI: 0.89, 0.95)”
Hazard ratio for heart failure, per 5 mm Hg SBP reduction“0.87 (95% CI: 0.83, 0.92)”
Relative risk for ESKD, per 10 mm Hg SBP reduction“0.95 (95% CI: 0.84, 1.07)”

ICER cost-effectiveness model: base-case results at the placeholder price

TreatmentIntervention acquisition costsNon-intervention costsTotal costsQALYsevLYsLYs
Lorundrostat (placeholder price)“$28,500”“$122,200”“$150,700”“9.54”“9.54”“11.86”
Baxdrostat“$27,600”“$122,000”“$149,600”“9.55”“9.55”“11.87”
Spironolactone“$200”“$122,600”“$122,800”“9.52”“9.52”“11.83”
Eplerenone“$2,000”“$122,200”“$124,300”“9.54”“9.54”“11.86”
Amiloride“$830”“$122,500”“$123,400”“9.52”“9.52”“11.84”
Treatment and comparatorCost per QALY gainedCost per evLY gainedCost per life year gained
Lorundrostat (placeholder price) vs. spironolactone“$1,419,000”“$1,327,000”“$1,213,000”
Lorundrostat (placeholder price) vs. eplerenone“More costly, less effective”“More costly, less effective”“More costly, less effective”
Lorundrostat (placeholder price) vs. amiloride“$1,492,000”“$1,403,000”“$1,273,000”
Baxdrostat vs. spironolactone“$833,000”“$781,000”“$712,000”
Baxdrostat vs. eplerenone“$2,077,000”“$1,954,000”“$1,774,000”
Baxdrostat vs. amiloride“$851,000”“$800,000”“$727,000”

ICER cost-effectiveness model: sensitivity and probabilistic analyses

Lorundrostat (placeholder price) compared withCost-effective at $50,000 per evLY gainedCost-effective at $100,000 per evLY gainedCost-effective at $150,000 per evLY gainedCost-effective at $200,000 per evLY gained
Spironolactone“0.0%”“0.0%”“0.0%”“0.0%”
Eplerenone“0.0%”“0.0%”“0.0%”“0.2%”
Amiloride“0.0%”“0.0%”“0.0%”“0.2%”

ICER cost-effectiveness model: scenario analyses

Scenario (cost per QALY gained, lorundrostat at the placeholder price)Compared with spironolactoneCompared with eplerenoneCompared with amiloride
Modified societal perspective“$1,404,000”“Lower effect, higher cost”“$1,479,000”
Same discontinuation for all treatments“$1,322,000”“$16,455,000”“$1,382,000”
No discontinuation for all treatments“Lower effect, higher cost”“$16,956,000”“$1,436,000”
10-year treatment effect duration“$1,698,000”“Lower effect, higher cost”“$1,577,000”
20-year treatment effect duration“$1,437,000”“Lower effect, higher cost”“$1,498,000”
5-year time horizon“$28,854,000”“$166,418,000”“$10,593,000”
10-year time horizon“$5,392,000”“$123,253,000”“$3,622,000”
Minimum price for generic comparators“$1,428,000”“Lower effect, higher cost”“$1,521,000”

ICER health-benefit price benchmark and threshold prices

Intervention and outcome measureAnnual WACAnnual price at $100,000 thresholdAnnual price at $150,000 thresholdDiscount from WAC to reach threshold prices
Lorundrostat, QALYs gained (placeholder price)“$10,950”“$760”“$1,500”“86.3% - 93.0%”
Lorundrostat, evLYs gained (placeholder price)“$10,950”“$770”“$1,600”“85.7% - 93.0%”
Baxdrostat, QALYs gained“$10,950”“$1,400”“$2,400”“78.3% - 87.4%”
Baxdrostat, evLYs gained“$10,950”“$1,400”“$2,500”“77.2% - 87.1%”
Lorundrostat compared with (QALY-based)Annual price to achieve $50,000 per QALY gainedAnnual price to achieve $100,000 per QALY gainedAnnual price to achieve $150,000 per QALY gainedAnnual price to achieve $200,000 per QALY gained
Spironolactone“$600”“$980”“$1,400”“$1,700”
Eplerenone“$770”“$770”“$760”“$760”
Amiloride“$790”“$1,100”“$1,500”“$1,900”

Published cost-effectiveness analyses of lorundrostat other than the ICER assessment

No evidence found.

Published cost-effectiveness analyses of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension

No evidence found.

Budget impact model

Approach and framework

Perspective and time frame

Epidemiology and eligible population inputs

ICER potential budget impact analysis: eligible population and uptake

“To estimate the size of Population 1 (those taking three or more antihypertensive medications but still not achieving blood pressure goals), we used inputs for the overall prevalence of hypertension among US adults (48.1%)” (opens the source at this quote in a new tab)

“the percentage of those with hypertension who are taking medication (51.2%)” (opens the source at this quote in a new tab)

“and the percentage of those taking medication who are being treated with three or more antihypertensive medications but still have uncontrolled hypertension (15%)” (opens the source at this quote in a new tab)

“Applying these sources to the overall adult population in the US averaged over the next five years (271,862,765) results in estimates of 10,042,828 eligible patients in the US. For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 2,008,565 patients per year.” (opens the source at this quote in a new tab)

“who are being treated with two antihypertensive medications and still have uncontrolled hypertension (17.9%)” (opens the source at this quote in a new tab)

“We then assumed that 21% of these have attempted a third antihypertensive medication and discontinued. This is a placeholder estimate based on available claims data reporting discontinuation rate of antihypertensive medications” (opens the source at this quote in a new tab)

“As a result, we estimated that 2,516,732 patients have uncontrolled hypertension and have attempted and discontinued a third antihypertensive medication (Population 2). For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 503,346 patients per year. Between Population 1 and Population 2 we estimated a total of 12,559,560 eligible patients.” (opens the source at this quote in a new tab)

Cost assumptions

ICER drug prices: baxdrostat, lorundrostat placeholder, and generic comparators
DrugWAC per doseNet price per doseNet price per year
Spironolactone (25 mg)“$0.117”“$0.117”“$43”
Spironolactone (100 mg)“$0.4683”“$0.4683”“$171”
Eplerenone (50 mg)“$1.3997”“$1.3997”“$511”
Eplerenone (100 mg)“$2.793”“$2.793”“$1,022”
Amiloride (5 mg)“$0.5627”“$0.5627”“$206”
Amiloride (10 mg)“$1.1253”“$1.1253”“$411”
Intervention (dosage)WAC per doseNet annual costSource
Lorundrostat (50 mg/day)“$30”“$10,950”“Placeholder”
Baxdrostat (2 mg/day)“$30”“$10,950”“Redbook”
Spironolactone (25–100 mg/day)“$0.12–$0.47”“$43–$171”“Redbook”
Eplerenone (50–100 mg/day)“$1.40–$2.79”“$511–$1,022”“Redbook”
Amiloride (5–10 mg/day)“$0.56–$1.13”“$206–$411”“Redbook”
ICER dosing regimens costed
Comparator acquisition cost: National Average Drug Acquisition Cost, spironolactone 25 mg
Comparator acquisition cost: National Average Drug Acquisition Cost, eplerenone 50 mg
FieldQuoted record
NDC description“EPLERENONE 50 MG TABLET”
NADAC per unit“0.47438”
Effective date“2026-11-18”
Comparator acquisition cost: National Average Drug Acquisition Cost, amiloride 5 mg
FieldQuoted record
NDC description“AMILORIDE HCL 5 MG TABLET”
NADAC per unit“0.20688”
Effective date“2026-11-18”
Comparator acquisition cost: National Average Drug Acquisition Cost, baxdrostat 2 mg
FieldQuoted record
NDC description“BAXFENDY 2 MG TABLET”
NADAC per unit“28.78424”
Effective date“2026-11-18”

Model outcomes

Results

Base case
Scenario analyses

Budget impact model discussion

Summary

No budget impact model of lorundrostat from Mineralys or a health plan was identified; the only budget impact analysis is ICER's potential budget impact analysis in its 2026 evidence report, which uses a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost ($900 for 30 tablets). The analysis takes the cost-effectiveness model's health care costs, undiscounted, over five years, against an even split of spironolactone, eplerenone, and amiloride, whose median generic acquisition costs in ICER's model were $43 to $1,022 per year. It sized 10,042,828 United States adults with resistant hypertension on three or more drugs (Population 1) and 2,516,732 on two drugs who discontinued a third (Population 2, based on a 21% placeholder discontinuation estimate), 12,559,560 in total, and assumed 20% would initiate treatment in each year. At the placeholder price, the cumulative budget impact per patient treated was about $8,500 in year one and $16,300 by year five, and about 2% of eligible patients could be treated before annual spending reached ICER's threshold of $821 million; at the threshold prices, 100% could be treated against eplerenone and at the $50,000 per evLY prices against spironolactone ($630) and amiloride ($810). ICER did not size Population 3, patients on two drugs who have not tried a third, which overlaps the company's stated “third line or later” target. The analysis reports national figures and does not model a health plan membership; a 2026 poster hosted on the Mineralys website estimates, for a hypothetical 1 million–member plan, 194,140 treated adults with hypertension, 104,494 with uncontrolled hypertension, and 37,081 receiving three or more drugs. The actual budget impact will depend on a lorundrostat price not yet announced (Mineralys has referred to an SGLT2 inhibitor or Entresto price point at WAC and has given no rebate guidance), on rebates, and on displacement of baxdrostat, whose NADAC was $28.78424 per 2 mg tablet on 18 November 2026, and of generic mineralocorticoid receptor antagonists and amiloride, whose NADAC ranged from $0.04218 to $0.47438 per tablet.